Does Skin Cancer Show Up on a PET Scan?

PET scans can detect many skin cancers, but how well they do so varies enormously depending on the type of skin cancer, how advanced it is, and where in the body you’re looking. For melanoma that has spread beyond the original site, a PET/CT scan is one of the preferred imaging tools and often catches metastases that other imaging misses. For early-stage disease or the most common form of skin cancer, basal cell carcinoma, the results are far less reliable. The answer, then, is less about whether PET scans “can” show skin cancer and more about when they’re the right tool for the job.

What a PET Scan Actually Picks Up

A PET scan works by tracking a radioactive sugar molecule (FDG) that gets injected into your bloodstream. Cancer cells tend to burn through glucose faster than normal tissue, so they absorb more of this tracer and light up on the scan. That basic principle gives PET scans high sensitivity for many aggressive tumors.¹ The catch is that anything with high metabolic activity can light up, including infections, inflammation, and healing tissue after surgery. And slower-growing cancers that don’t consume much glucose can stay dark.

In practice, PET is almost always combined with a CT scan (PET/CT), which layers the metabolic information from PET onto the detailed anatomical images from CT. That combination is what most people mean when they talk about getting “a PET scan” for cancer.

Where PET Scans Work Best for Melanoma

Melanoma is the skin cancer most commonly evaluated with PET, and for good reason. Once melanoma has reached stage III or IV, meaning it has spread to nearby lymph nodes or to distant organs, PET/CT becomes a powerful staging tool. A systematic review of advanced cutaneous melanoma found that PET/CT has high overall accuracy for detecting distant metastases and is, when paired with brain MRI, the preferred imaging strategy for staging metastatic melanoma.²

The scan’s value is especially clear in the preoperative setting. In patients with surgically treatable metastatic melanoma, PET/CT has been shown to detect unexpected metastases that conventional imaging, such as standard CT or ultrasound, either missed or never imaged in the first place.³ Finding those hidden deposits before an operation can change the entire surgical plan or shift a patient to a different treatment approach altogether.

A study of 73 patients initially classified as stage III found that PET/CT bumped roughly one in five of them up to stage IV by revealing distant disease that hadn’t been caught before. That restaging directly changed their treatment.⁴ When a scan reclassifies your cancer stage, it often means the difference between surgery with intent to cure and systemic therapy aimed at controlling the disease.

When PET Scans Miss Melanoma

The picture is much less rosy for early-stage melanoma. If your melanoma is still confined to the skin or has only reached microscopic deposits in nearby lymph nodes, PET is unreliable. One study looking at patients with stage I or II melanoma found the scan had a sensitivity of only about 14% for detecting subclinical lymph node metastases. In other words, it missed the vast majority of them.⁵ That same study concluded that PET/CT simply cannot replace sentinel lymph node biopsy, which is the standard procedure for checking whether early-stage melanoma has spread to the nearest nodes. The biopsy had 100% sensitivity by comparison.

The reason PET struggles here is straightforward: small clusters of cancer cells don’t consume enough glucose to stand out from the background noise. A metastatic deposit smaller than about a centimeter often flies under the radar. A case report documented PET missing cutaneous melanoma metastases despite what the researchers described as significant tumor size and thickness, underscoring that even larger lesions can occasionally escape detection depending on their biology.¹

The Brain Is a Blind Spot

One of the biggest limitations of PET for melanoma involves the brain. Melanoma has a well-known tendency to spread there, and you might assume a whole-body PET scan would catch brain metastases. It usually doesn’t. Your brain tissue is already one of the hungriest glucose consumers in your body, so the high background metabolic activity masks the signal from tumor deposits.

A five-year study of nearly 400 melanoma patients compared PET/CT head-to-head with brain MRI for detecting cerebral metastases. Among 47 patients with confirmed brain involvement, PET/CT fully detected the metastases in only about 4% of cases. In roughly two-thirds of those patients, PET/CT missed the brain lesions entirely.⁶ This is why guidelines for staging advanced melanoma consistently recommend adding a dedicated brain MRI on top of any PET scan.

Basal Cell Carcinoma

Basal cell carcinoma (BCC) is by far the most common skin cancer, but it’s rarely a reason to order a PET scan. Most BCCs are slow-growing, locally destructive tumors that almost never spread to distant sites. They’re typically treated with excision or other local procedures, and imaging beyond the skin surface isn’t needed.

In the rare cases of advanced BCC that has invaded deeply or spread, PET results are inconsistent. A small study of head-and-neck BCCs found that PET correlated well with tumor extent in nodular-type tumors but failed to detect activity in half the cases, particularly in the infiltrative subtype. One tumor with perineural spread, where cancer tracks along nerves, was confirmed by biopsy but invisible on PET.⁷

That said, when BCC does become advanced enough to warrant systemic treatment, PET can play a role in monitoring whether therapy is working. A study of patients with advanced BCC treated with the targeted drug vismodegib found that all subjects had at least one lesion that lit up on PET. A decrease of about a third or more in the scan’s metabolic measurement was associated with longer survival.⁸ So while PET isn’t a diagnostic tool for typical BCC, it has a niche in tracking response for the small fraction of cases that become aggressive enough to need systemic drugs.

Squamous Cell Carcinoma of the Skin

Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer. Like BCC, most cases are treated locally and never need advanced imaging. But a subset of SCCs, especially those on the head and neck, in immunosuppressed patients, or with high-risk features, can spread to lymph nodes and beyond.

For that high-risk group, PET/CT shows promise. In one study of 23 patients with cutaneous SCC who underwent staging PET/CT, the scan detected nine previously unknown metastatic lesions in five patients. That changed management for about one in five patients in the cohort.⁹ The evidence base is still small compared to melanoma, but PET/CT appears particularly useful for patients whose immune systems are compromised, such as organ transplant recipients or people with certain blood cancers, since their SCCs tend to behave more aggressively.¹⁰

Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is rare but aggressive, and it’s one of the skin cancers where PET performs best. A pooled analysis of nine studies covering 259 patients found that PET or PET/CT achieved a sensitivity of about 91% and a specificity of about 93% for detecting MCC across all sites.¹¹ Those numbers are considerably better than what PET achieves for early melanoma or BCC.

Because MCC tends to spread quickly to lymph nodes and distant sites, catching occult metastases early matters a lot for treatment planning. PET/CT is increasingly considered a key part of MCC workup, helping to document disease burden and guide decisions about surgery, radiation, and immunotherapy.¹²

False Positives and Why They Matter

A PET scan lighting up doesn’t always mean cancer. FDG is not a cancer-specific molecule. Infections, including bacterial, fungal, and mycobacterial infections, can all produce intense uptake. So can sarcoidosis, inflammation from radiation therapy, and post-surgical healing.¹³ If you’ve recently had surgery on a skin cancer site or an infection near the area being scanned, a hot spot on PET may have nothing to do with cancer recurrence.

This is one of the practical reasons PET isn’t used as a screening tool for skin cancer in the general population. In people without a known cancer diagnosis, a glowing spot creates anxiety and often leads to biopsies or additional imaging that turn out to be unnecessary. PET scans earn their keep in specific clinical scenarios, primarily staging known advanced disease, not as a first-line search for skin cancer.

The flip side, false negatives, is equally important. As discussed with early melanoma and certain BCC subtypes, a clean PET scan doesn’t guarantee you’re cancer-free. Small deposits, slow-growing tumors, and brain metastases can all escape detection. Your doctor will interpret a PET result alongside pathology, physical examination, and often other imaging modalities rather than relying on it alone.

Tracking Response to Immunotherapy

One of the fastest-growing uses of PET in skin cancer isn’t staging at all. It’s monitoring how well treatment is working, especially with immune checkpoint inhibitors that have become standard therapy for advanced melanoma and MCC. PET-based metabolic measurements are emerging as useful biomarkers for predicting and assessing response to these drugs.¹⁴ Multiple standardized criteria for interpreting PET scans during immunotherapy have been tested, and a multicenter comparison found that all three major scoring systems accurately evaluated treatment response and predicted survival in melanoma patients receiving checkpoint inhibitors.¹⁵

There is, however, a tricky phenomenon called pseudoprogression. When immunotherapy activates the immune system against a tumor, the influx of immune cells can temporarily cause a lesion to look bigger or more metabolically active on PET. To a radiologist reading the scan, it can look like the cancer is getting worse when it’s actually responding. A study of metastatic melanoma patients starting immunotherapy found that pseudoprogression on PET occurred in roughly 2.5% of cases, with the true response becoming apparent on follow-up scans about six months later on average.¹⁶ Though uncommon, this finding reinforces why early PET results alone shouldn’t prompt doctors to abandon an immunotherapy regimen that may ultimately be working.

Incidental Skin Cancers Found on PET

Sometimes the scenario is reversed: a PET scan ordered for an entirely different cancer reveals a previously unknown malignancy. In a study of over 1,900 patients undergoing PET/CT, about 4% had suspicious spots suggesting a new primary cancer, and in roughly 1.2% the additional tumors were pathologically confirmed. The most common sites were the lung, thyroid, and colon, but the principle applies to skin lesions too.¹⁷ A hypermetabolic skin lesion found incidentally on PET would typically prompt a biopsy rather than be assumed cancerous. Still, PET has occasionally been the reason an unsuspected skin cancer was caught.

Cutaneous Versus Mucosal Melanoma on PET

Not all melanomas behave the same on PET. A study comparing cutaneous melanoma (the kind arising from sun-exposed skin) with mucosal melanoma (which develops in internal mucous membranes like the nasal passages or mouth) found that lung metastases from mucosal melanoma showed significantly higher metabolic activity on PET than those from cutaneous melanoma. Other metastatic sites, including bone, liver, and lymph nodes, did not differ meaningfully between the two types.¹⁸ The takeaway is that the biological origin of a melanoma can influence how bright it appears on PET in certain organs, which matters when radiologists interpret scans and compare lesions across patients.

New Tracers Beyond FDG

FDG has been the workhorse tracer for PET since the technology entered mainstream oncology, but it has well-documented blind spots. Researchers are developing new PET tracers designed to target specific features of skin cancer rather than just glucose consumption. For melanoma specifically, four main groups of experimental tracers are in the pipeline. Melanin-targeted tracers bind directly to the pigment that melanoma cells produce, which could make detection far more specific. Fibroblast activation protein (FAP) inhibitors target the supportive tissue around tumors. Meanwhile, tracers aimed at PD-1/PD-L1 and CD8+ T cells are designed less for diagnosis and more for predicting whether a patient will respond to immunotherapy.¹⁹

These tracers are still in clinical development, but they represent a shift in thinking about what PET can do for skin cancer. Instead of just asking “where is the cancer?” future PET scans could help answer “will this treatment work for this patient?” That second question is arguably more valuable for the growing number of melanoma patients being offered immunotherapy, where response rates are far from universal and early prediction of benefit could spare months of ineffective treatment.